The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Polymorphisms in FcγRIIIA (CD16) Receptor Expression Are Associated With Clinical Response to Rituximab in Waldenström’s Macroglobulinemia
Abstract
Purpose: Rituximab is an important therapeutic for Waldenström’s macroglobulinemia (WM). Polymorphisms in FcγRIIIA (CD16) receptor expression modulate human immunoglobulin G1 binding and antibody-dependent cell-mediated cytotoxicity, and may therefore influence responses to rituximab. Patients and Methods: Sequence analysis of the entire coding region of FcγRIIIA was undertaken in 58 patients with WM whose outcomes after rituximab were known. Results: Variations in five codons of FcγRIIIA were identified. Two were commonly observed (FcγRIIIA-48 and FcγRIIIA-158) and predicted for amino acid polymorphisms at FcγRIIIA-48: leucine/leucine (L/L), leucine/arginine (L/R), and leucine/histidine (L/H). Polymorphisms at FcγRIIIA-158 were phenylalanine/phenylalanine (F/F), phenylalanine/valine (F/V), and valine/valine (V/V). A clear linkage between these polymorphisms was detected and all patients with FcγRIIIA-158F/F were always FcγRIIIA-48L/L, and patients with either FcγRIIIA-L/R or -L/H always expressed at least one valine at FcγRIIIA-158 (P ≤ .001). The response trend was higher for patients with FcγRIIIA-48L/H (38.5%) versus -48L/R (25.0%) and LL (22.0%), and was significantly higher for patients with FcγRIIIA-158V/V (40.0%) and -V/F (35%) versus -158F/F (9.0%; P = .030). Responses for patients with FcγRIIIA-48L/L were higher when at least one valine was present at FcγRIIIA-158 (P = .057), thereby supporting a primary role for FcγRIIIA-158 polymorphisms in predicting rituximab responses. With a median follow-up of 13 months, no significant differences in the median time to progression and progression-free survival were observed when patients were grouped according to their FcγRIIIA-48 and -158 polymorphisms. Conclusion: The results of these studies therefore support a predictive role for FcγRIIIA-158 polymorphisms and responses to rituximab in WM.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cartron, G., Dacheux, L., Salles, G., Solal-Celigny, P., Bardos, P., Colombat, P., & Watier, H. (2002) · Blood · doi:10.1182/blood.v99.3.754 · Cited by 1,900
Weng, W.-K., & Levy, R. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.05.013 · Cited by 1,300
Shields, R. L., Namenuk, A. K., Hong, K., Meng, Y. G., Rae, J., Briggs, J., Xie, D., Lai, J., Stadlen, A., Li, B., et al. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m009483200 · Cited by 1,161
Koene, H. R., Kleijer, M., Algra, J., Roos, D., E.G.Kr. von dem Borne, A., & de Haas, M. (1997) · Blood · doi:10.1182/blood.v90.3.1109 · Cited by 794
Wu, J., Edberg, J. C., Redecha, P. B., Bansal, V, Guyre, P. M., Coleman, K., Salmon, J. E., & Kimberly, R. P. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119616 · Cited by 711
Anolik, J. H., Campbell, D., Felgar, R. E., Young, F., Sanz, I., Rosenblatt, J., & Looney, R. J. (2003) · Arthritis & Rheumatism · doi:10.1002/art.10764 · Cited by 429
Treatment of Waldenström’s Macroglobulinemia With Rituximab
Dimopoulos, M. A., Zervas, C., Zomas, A., Kiamouris, C., Viniou, N. A., Grigoraki, V., Karkantaris, C., Mitsouli, C., Gika, D., Christakis, J., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.09.039 · Cited by 253
Farag, S. S., Flinn, I. W., Modali, R., Lehman, T. A., Young, D., & Byrd, J. C. (2004) · Blood · doi:10.1182/blood-2003-07-2548 · Cited by 210
Treon, S. P., Mitsiades, C., Mitsiades, N., Young, G., Doss, D., Schlossman, R., & Anderson, K. C. (2001) · Journal of Immunotherapy · doi:10.1097/00002371-200105000-00011 · Cited by 205
Self-citationPhase I Studies of Interleukin (IL)-2 and Rituximab in B-Cell Non-Hodgkin’s Lymphoma
Gluck, W. L., Hurst, D., Yuen, A., Levine, A. M., Dayton, M. A., Gockerman, J. P., Lucas, J., Denis-Mize, K., Tong, B., Navis, D., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-1087-3 · Cited by 166
Cited by
Rituximab: Mechanism of Action
Weiner, G. J. (2010) · Seminars in Hematology · doi:10.1053/j.seminhematol.2010.01.011 · Cited by 786
Cancer Immunotherapy Comes of Age
Topalian, S. L., Weiner, G. J., & Pardoll, D. M. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.0899 · Cited by 586
Immunotherapy targeting 4-1BB: mechanistic rationale, clinical results, and future strategies
Chester, C., Sanmamed, M. F., Wang, J., & Melero, I. (2018) · Blood · doi:10.1182/blood-2017-06-741041 · Cited by 499
Rituximab-Dependent Cytotoxicity by Natural Killer Cells
Dall’Ozzo, S., Tartas, S., Paintaud, G., Cartron, G., Colombat, P., Bardos, P., Watier, H., & Thibault, G. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-2862 · Cited by 434
Liu, L. (2015) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.24444 · Cited by 428
Metadata
- Authors
- Treon, S. P., Hansen, M., Branagan, A. R., Verselis, S., Emmanouilides, C., Kimby, E., Frankel, S. R., Touroutoglou, N., Turnbull, B., Anderson, K. C., Maloney, D. G., & Fox, E. A.
- Venue
- Journal of Clinical Oncology
- Published
- 2005-01-20
- Volume
- 23
- Issue
- 3
- Pages
- 474-481
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2109638333
- Cited by
- 263
- References
- 14
- FWCI
- 11.96
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Polymorphisms in FcγRIIIA (CD16) Receptor Expression Are Associated With Clinical Response to Rituximab in Waldenström’s Macroglobulinemia. https://app.cochat.ai/papers/10.1200/jco.2005.06.059
- The paper
- Treon, S. P., Hansen, M., Branagan, A. R., Verselis, S., Emmanouilides, C., Kimby, E., Frankel, S. R., Touroutoglou, N., Turnbull, B., Anderson, K. C., Maloney, D. G., & Fox, E. A. (2005). Polymorphisms in FcγRIIIA (CD16) Receptor Expression Are Associated With Clinical Response to Rituximab in Waldenström’s Macroglobulinemia. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2005.06.059
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
